Urologix Inc
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides P… Read more
Urologix Inc (ULGX) - Net Assets
Latest net assets as of March 2015: $-8.06 Million USD
Based on the latest financial reports, Urologix Inc (ULGX) has net assets worth $-8.06 Million USD as of March 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.02 Million) and total liabilities ($13.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.06 Million |
| % of Total Assets | -160.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | -185.02% |
| 10-Year Change | -121.05% |
| Growth Volatility | 452.86 |
Urologix Inc - Net Assets Trend (1995–2014)
This chart illustrates how Urologix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Urologix Inc (1995–2014)
The table below shows the annual net assets of Urologix Inc from 1995 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-06-30 | $-6.98 Million | -1761.19% |
| 2013-06-30 | $420.00K | -32.91% |
| 2012-06-30 | $626.00K | -87.08% |
| 2011-06-30 | $4.85 Million | -40.95% |
| 2010-06-30 | $8.21 Million | -17.32% |
| 2009-06-30 | $9.93 Million | -28.32% |
| 2008-06-30 | $13.85 Million | -50.32% |
| 2007-06-30 | $27.88 Million | -30.28% |
| 2006-06-30 | $39.98 Million | +20.62% |
| 2005-06-30 | $33.15 Million | +7.90% |
| 2004-06-30 | $30.72 Million | +5.54% |
| 2003-06-30 | $29.11 Million | -25.27% |
| 2002-06-30 | $38.95 Million | -1.42% |
| 2001-06-30 | $39.51 Million | +37.33% |
| 2000-06-30 | $28.77 Million | -18.96% |
| 1999-06-30 | $35.50 Million | -27.99% |
| 1998-06-30 | $49.30 Million | +52.16% |
| 1997-06-30 | $32.40 Million | -20.20% |
| 1996-06-30 | $40.60 Million | +915.00% |
| 1995-06-30 | $4.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Urologix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11572600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $209.00K | % |
| Other Components | $119.44 Million | % |
| Total Equity | $-6.98 Million | 100.00% |
Urologix Inc Competitors by Market Cap
The table below lists competitors of Urologix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Velocity Energy Inc
PINK:VCYE
|
$0.98 |
|
Patient Portal Technologies Inc
PINK:PPRG
|
$0.98 |
|
Great American Financial Corporation
PINK:GAFL
|
$0.98 |
|
For The Earth Corp
PINK:FTEG
|
$0.98 |
|
Interplay Entertainment Corp
PINK:IPLY
|
$0.98 |
|
MabCure Inc
PINK:MBCI
|
$0.98 |
|
Pacific Conquest Holdings Inc
PINK:PCHK
|
$0.98 |
|
Andatee China Marine Fuel Services
PINK:AMCF
|
$0.98 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Urologix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from 420,000 to -6,977,000, a change of -7,397,000 (-1761.2%).
- Net loss of 7,608,000 reduced equity.
- Other factors increased equity by 211,000.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.61 Million | -109.04% |
| Other Changes | $211.00K | +3.02% |
| Total Change | $- | -1761.19% |
Book Value vs Market Value Analysis
This analysis compares Urologix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-06-30 | $2.04 | $0.00 | x |
| 1996-06-30 | $6.41 | $0.00 | x |
| 1997-06-30 | $3.48 | $0.00 | x |
| 1998-06-30 | $4.73 | $0.00 | x |
| 1999-06-30 | $3.12 | $0.00 | x |
| 2000-06-30 | $2.50 | $0.00 | x |
| 2001-06-30 | $3.10 | $0.00 | x |
| 2002-06-30 | $2.82 | $0.00 | x |
| 2003-06-30 | $2.09 | $0.00 | x |
| 2004-06-30 | $2.10 | $0.00 | x |
| 2005-06-30 | $2.25 | $0.00 | x |
| 2006-06-30 | $2.78 | $0.00 | x |
| 2007-06-30 | $1.94 | $0.00 | x |
| 2008-06-30 | $0.97 | $0.00 | x |
| 2009-06-30 | $0.69 | $0.00 | x |
| 2010-06-30 | $0.57 | $0.00 | x |
| 2011-06-30 | $0.33 | $0.00 | x |
| 2012-06-30 | $0.04 | $0.00 | x |
| 2013-06-30 | $0.02 | $0.00 | x |
| 2014-06-30 | $-0.33 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Urologix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -53.45%
- • Asset Turnover: 2.51x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-118.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -135.00% | -1080.00% | 0.10x | 1.23x | $-5.80 Million |
| 1996 | -18.72% | -1900.00% | 0.01x | 1.04x | $-11.66 Million |
| 1997 | -25.31% | -149.09% | 0.15x | 1.10x | $-11.44 Million |
| 1998 | -30.43% | -133.93% | 0.21x | 1.09x | $-19.93 Million |
| 1999 | -39.72% | -231.15% | 0.16x | 1.10x | $-17.65 Million |
| 2000 | -24.67% | -86.95% | 0.26x | 1.11x | $-9.97 Million |
| 2001 | -13.00% | -33.48% | 0.33x | 1.19x | $-9.09 Million |
| 2002 | -4.24% | -7.26% | 0.49x | 1.19x | $-5.55 Million |
| 2003 | -34.52% | -53.52% | 0.52x | 1.23x | $-12.96 Million |
| 2004 | 2.09% | 2.64% | 0.67x | 1.18x | $-2.43 Million |
| 2005 | 8.56% | 10.99% | 0.66x | 1.18x | $-477.50K |
| 2006 | 13.74% | 21.22% | 0.59x | 1.10x | $1.50 Million |
| 2007 | -47.49% | -62.10% | 0.65x | 1.17x | $-16.02 Million |
| 2008 | -107.58% | -99.94% | 0.85x | 1.26x | $-16.28 Million |
| 2009 | -44.52% | -34.48% | 1.06x | 1.22x | $-5.41 Million |
| 2010 | -26.43% | -14.68% | 1.45x | 1.24x | $-2.99 Million |
| 2011 | -77.03% | -29.70% | 1.86x | 1.40x | $-4.22 Million |
| 2012 | -750.00% | -27.57% | 1.34x | 20.25x | $-4.76 Million |
| 2013 | -1021.90% | -25.87% | 1.32x | 29.83x | $-4.33 Million |
| 2014 | 0.00% | -53.45% | 2.51x | 0.00x | $-6.91 Million |
Industry Comparison
This section compares Urologix Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Urologix Inc (ULGX) | $-8.06 Million | -135.00% | N/A | $0.98 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |